When a nerve impulse arrives at a 5-HT or noradrenaline nerve terminal the neurotransmitter is released from the synaptic vesicle into the synaptic cleft. Neurotransmitter molecules bind to their specific receptors on the post-synaptic membrane and the nerve impulse is propagated or inhibited, depending on the receptor type. 5-HT and noradrenaline molecules are then released from their receptors and taken back into the nerve terminal via either the 5-HT or noradrenaline re-uptake transporters. 5-HT and noradrenaline are degraded by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT), these enzymes are found in the nerve terminal.1,2
Click here: Learn about the normal processes of serotonin and noradrenaline synaptic activity
Related content
Migraine is a prevalent neurological disorder characterized by recurrent and disabling attacks of moderate to severe headache
Migraine affects an estimated 1.1 billions worldwide and ranks as the 2nd leading cause of disability, while being the leading among young adults.
In human models of migraine, a suspected pharmacological migraine trigger is administered either orally or via infusion to a participant with migraine or a healthy volunteer, typically within a double-blinded, randomized, placebo-controlled design